Alto Neuroscience, Inc. SEC filings ANRO
Alto Neuroscience, Inc. has 196 filings in SEC EDGAR's recent list, going back to Nov 22, 2023. Its latest annual report, Form ARS, was filed on Mar 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 27, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Mar 26, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 16, 2026 | Dec 31, 2025 |
| ARS | Annual report to shareholders | Apr 1, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 20, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 21, 2024 | Dec 31, 2023 |
Showing 5 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANRO (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1999480
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.